Home Stock

Stock Research: Takeda Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Takeda Pharmaceutical

TYO:4502 JP3463000004
60
  • Value
    92
  • Growth
    71
  • Safety
    Safety
    10
  • Combined
    66
  • Sentiment
    63
  • 360° View
    360° View
    60
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Takeda Pharmaceutical Co Ltd is a pharmaceutical company focused on research, development, and sale of pharmaceuticals. It focuses on gastrointestinal diseases, rare diseases, oncology, and neuroscience. The company operates in Japan, the United States, Europe, and China. In the last fiscal year, the company had a market cap of $46758 million, profits of $20016 million, and revenue of $30554 million, with 47455 employees.

more

ANALYSIS: With an Obermatt 360° View of 60 (better than 60% compared with alternatives), overall professional sentiment and financial characteristics for the stock Takeda Pharmaceutical are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Takeda Pharmaceutical. The consolidated Value Rank has an attractive rank of 92, which means that the share price of Takeda Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 92% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 71, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 63. But the company’s financing is risky with a Safety rank of 10. This means 90% of comparable companies have a safer financing structure than Takeda Pharmaceutical. ...read more

more
Strongest Rank Safety
Weakest Rank Profit Growth
Country Japan
Industry Pharmaceuticals
Size XX-Large
Website takeda.com
Index
TOPIX 100
Nikkei 225
Takeda Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
92 80 74 95
Growth
71 32 3 11
Safety
Safety
10 7 6 8
Sentiment
63 30 8 8
360° View
360° View
60 24 6 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
34 33 33 37
Opinions Change
50 83 24 50
Pro Holdings
n/a 24 14 32
Market Pulse
63 28 20 19
Sentiment
63 30 8 8
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
92 80 74 95
Growth
71 32 3 11
Safety Safety
10 7 6 8
Combined
66 18 6 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
52 72 64 76
Price vs. Earnings (P/E)
61 26 30 71
Price vs. Book (P/B)
80 83 73 87
Dividend Yield
97 93 98 96
Value
92 80 74 95
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
14 8 15 11
Profit Growth
100 23 6 14
Capital Growth
12 68 21 37
Stock Returns
93 60 49 65
Growth
71 32 3 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
20 14 7 4
Refinancing
18 19 11 25
Liquidity
51 16 22 18
Safety Safety
10 7 6 8

Similar Stocks

Discover high‑ranked alternatives to Takeda Pharmaceutical and broaden your portfolio horizons.

Brother Industries

TYO:6448
Country: Japan
Industry: Technology Hardware & Peripherals
Size: X-Large
Full Stock Analysis

Cosmo Energy Holdings

TYO:5021
Country: Japan
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

Shimadzu

TYO:7701
Country: Japan
Industry: Electronic Equipment
Size: X-Large
Full Stock Analysis

NSK

TYO:6471
Country: Japan
Industry: Industrial Machinery
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews